This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Antibody-dependent cellular cytotoxicity-null effector developed using mammalian and plant GlycoDelete platform
Scientific Reports Open Access 08 November 2022
-
Characterisation of a highly potent and near pan-neutralising anti-HIV monoclonal antibody expressed in tobacco plants
Retrovirology Open Access 28 June 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Piron, R., Santens, F., De Paepe, A., Depicker, A. & Callewaert, N. Nat. Biotechnol. 33, 1135–1137 (2015).
Meuris, L. et al. Nat. Biotechnol. 32, 485–489 (2014).
Bardor, M. et al. Glycobiol. 13, 427–434 (2003).
Landry, N. et al. PLoS One 5, e15559 (2010).
Ward, B.J. et al. Vaccine 32, 6098–6106 (2014).
US Food and Drug Administration. Guidance for Industry, Safety Labeling Changes—Implementation of Section 505(o)(4) of the FD&C Act. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm250783.pdf (FDA, July 2013).
Tekoah, Y. et al. Plant Biotechnol. J. 13, 1199–1208 (2015).
US Food and Drug Administration. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022458s003s006lbl.pdf (2014).
Broomfield, A., Jones, S.A., Hughes, S.M. & Bigger, B. W. J. Inherit. Metab. Dis. doi:10.1007/s10545-016-9917-1 (2016).
US Food and Drug Administration. Cerezyme (imiglucerase for injection): proposed text of the labeling of the drug. http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/20367s066lbl.pdf (FDA, March 2003).
US Food and Drug Administration. Highlights of prescribing information for VPRIV. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022575s017lbl.pdf (FDA, April 2015).
European Medicines Agency. European public assessment report (EPAR) summary for the public for Cerezyme. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000157/WC500024108.pdf
Bosch, D., Castilho, A., Loos, A., Schots, A. & Steinkellner, H. Curr. Pharm. Des. 19, 5503–5512 (2013).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors are employees of Protalix Ltd.
Rights and permissions
About this article
Cite this article
Shaaltiel, Y., Tekoah, Y. Plant specific N-glycans do not have proven adverse effects in humans. Nat Biotechnol 34, 706–708 (2016). https://doi.org/10.1038/nbt.3556
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3556
This article is cited by
-
Antibody-dependent cellular cytotoxicity-null effector developed using mammalian and plant GlycoDelete platform
Scientific Reports (2022)
-
Characterisation of a highly potent and near pan-neutralising anti-HIV monoclonal antibody expressed in tobacco plants
Retrovirology (2021)
-
Comparison of CD20 Binding Affinities of Rituximab Produced in Nicotiana benthamiana Leaves and Arabidopsis thaliana Callus
Molecular Biotechnology (2021)
-
Cellular engineering of plant cells for improved therapeutic protein production
Plant Cell Reports (2021)